Kiniksa Pharmaceuticals International (KNSA) Interest & Investment Income (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Interest & Investment Income came in at -$715000.0 in Q2 2026, down 738.39% on a YoY basis from $112000.0 in Q2 2025, and down 11.72% quarter-over-quarter from -$640000.0 in Q1 2026.
Powered by 
Analysis
Kiniksa Pharmaceuticals International (KNSA) Interest & Investment Income (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has reported Interest & Investment Income for 10 consecutive years, with -$715000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Interest & Investment Income fell 738.39% year-over-year to -$715000.0; the trailing twelve-month figure through Jun 2026 stood at -$1.3 million (down 1823.38% YoY), and the FY2025 full-year result was $138000.0, up 181.66% from the prior year.
- Interest & Investment Income eased to -$715000.0 in Q2 2026 per KNSA's latest filing, from -$640000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $130000.0 in Q4 2025 and bottomed at -$715000.0 in Q2 2026.
- Historically, Interest & Investment Income has averaged -$73000.0 across 5 years, with a median of -$8000.0 in 2023.
- The sharpest annual moves came in 2024 and 2026: Interest & Investment Income jumped 735.71% in 2024, then tumbled 31900.0% in 2026.
- Over 5 years, Interest & Investment Income stood at $114000.0 in 2022, then sank by 93.86% to $7000.0 in 2023, then sank by 1842.86% to -$122000.0 in 2024, then soared by 206.56% to $130000.0 in 2025, then plunged by 650.0% to -$715000.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered -$715000.0, -$640000.0, and $130000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.05 Bn | 197.06 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.07 Bn | 177.90 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.15 Bn | 124.30 Bn | 2.84 Bn | 120.60 Mn |
| 4 | Regeneron Pharmaceuticals | 82.66 Bn | 74.67 Bn | 3.93 Bn | -48.00 Mn |
| 5 | Argenx Se | 61.74 Bn | 56.55 Bn | 1.37 Bn | 48.00 Mn |
| 6 | Moderna | 54.51 Bn | 49.37 Bn | 52.00 Mn | 67.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.05 Bn | 30.74 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Biogen | 31.25 Bn | 29.97 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.88 Bn | 29.88 Bn | 1.16 Mn | 36.92 Mn |
| 10 | Kiniksa Pharmaceuticals International | 6.15 Bn | 5.62 Bn | 220.03 Mn | -715,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -715,000.00 |
| Mar 31, 2026 | -640,000.00 |
| Dec 31, 2025 | 130,000.00 |
| Sep 30, 2025 | -102,000.00 |
| Jun 30, 2025 | 112,000.00 |
| Mar 31, 2025 | -2,000.00 |
| Dec 31, 2024 | -122,000.00 |
| Sep 30, 2024 | 89,000.00 |
| Jun 30, 2024 | -77,000.00 |
| Mar 31, 2024 | -59,000.00 |
| Dec 31, 2023 | 7,000.00 |
| Sep 30, 2023 | -14,000.00 |
| Jun 30, 2023 | -42,000.00 |
| Mar 31, 2023 | 11,000.00 |
| Dec 31, 2022 | 114,000.00 |
| Sep 30, 2022 | 20,000.00 |
| Jun 30, 2022 | 13,000.00 |
| Mar 31, 2022 | -37,000.00 |
| Dec 31, 2021 | -52,000.00 |
| Sep 30, 2021 | -72,000.00 |